% 0期刊文章%一露丝c . Shinnar %什洛莫Shinnar %一个佩吉·克拉克Avital克纳安% %丹尼斯Dlugos %黛博拉·g·Hirtz %一个凤鸣胡锦涛%春燕刘%大卫Masur %埃里卡·维斯%的特雷西·A .朱丽恩%儿童失神癫痫研究小组% T预处理行为和随后的治疗效果在儿童失神癫痫% D R 10.1212 / WNL 2017%。0000000000004514 % J首页神经病学% P 1698 - 1706 X % V 89% N 16%目的:描述预处理行为问题和微分作用的初始治疗儿童失神癫痫患儿(CAE)。方法:对儿童行为检查表(很高)管理基线,16 - 20周,和12月访问的随机双盲试验乙琥胺,拉莫三嗪、丙戊酸钠。总分数是主要的结果测量标准的问题。结果:共有382名参与者在基线,310名参与者在本周访问16 - 20日,168名参与者在12月开始的数据访问。在基线,8%(95%可信区间[CI] 6% - -11%)的儿童与CAE升高总得分(平均52.9±10.91)问题。在16 - 20周,参与者服用丙戊酸有明显高于总问题(51.7 (98.3% CI 48.6 - -54.7)),外化问题(51.4 (98.3% CI 48.5 - -54.3)),注意力问题(57.8 (98.3% CI 55.6 - -60.0)),和注意缺陷/多动问题(55.8 (98.3% CI 54.1 - -57.6))的分数相比,参与者乙琥胺(46.5 (98.3% CI 43.4 - -49.6);45.8 (98.3% CI 42.9 - -48.7);54.6 (98.3% CI 52.4 - -56.9);53.0 (98.3% CI 51.3 - -54.8))。缺乏没收自由和高周-康纳连续与严重的总问题相关的性能测试信心指数分数。在12月,参与者服用丙戊酸有显著更高的注意力问题的得分(57.9 (98.3% CI 55.6 - -60.3))相比,参与者采取乙琥胺(54.5 (95% CI 52.1 - -56.9))。结论:在CAE预处理和正在进行的行为问题存在。 Valproic acid is associated with worse behavioral outcomes than ethosuximide or lamotrigine, further reinforcing ethosuximide as the preferred initial therapy for CAE.Clinicaltrials.gov identifier: NCT00088452.Classification of evidence: This study provides Class II evidence that for children with CAE, valproic acid is associated with worse behavioral outcomes than ethosuximide or lamotrigine.ANCOVA=analysis of covariance; ANOVA=analysis of variance; CAE=childhood absence epilepsy; CBCL=Child Behavior Checklist; CI=confidence interval; CPT=Continuous Performance Test; DSM=Diagnostic and Statistical Manual of Mental Disorders; RCT=randomized controlled trial %U //www.ez-admanager.com/content/neurology/89/16/1698.full.pdf